Val-HeFT and angiotensin-receptor blockers in perspective: A tale of the blind man and the elephant
| Autor: | Marvin A. Konstam, Tognoni G, Cohn Jn |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
medicine.medical_specialty
Ejection fraction business.industry Captopril medicine.disease Sudden death law.invention Losartan Randomized controlled trial Valsartan law Heart failure Internal medicine ACE inhibitor Cardiology Medicine Cardiology and Cardiovascular Medicine business Intensive care medicine medicine.drug |
| Zdroj: | Journal of Cardiac Failure. 8:56-58 |
| ISSN: | 1071-9164 |
| DOI: | 10.1054/jcaf.2002.32950 |
| Popis: | EDITOR SUMMARY Background: The role of angiotensin-receptor blockers (ARBs) in the therapy of chronic heart failure (CHF) has not been clarified. There are no large placebo-controlled trials with these agents. The second Evaluation of Losartan in the Elderly trial (ELITE-II) compared the ARB losartan with captopril in 3,152 patients ≥60 years old with New York Heart Association (NYHA) class II-IV and left ventricular ejection fraction ≤40% and did not establish the efficacy of the ARB or its equivalent to angiotensin-converting enzyme inhibitor. The Valsartan Heart Failure Trial was designed to determine whether addition of valsartan improved the outcomes of patients receiving standard therapy for heart failure, which in most cases included an ACE inhibitor. Methods and Results: A total of 5,010 patients with NYHA class II-IV CHF and ejection fraction |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect